{"brief_title": "VELCADE\u00ae (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma", "brief_summary": "The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.", "condition": "Marginal Lymphoma", "intervention_type": "Drug", "intervention_name": "VELCADE and rituximab", "criteria": "Inclusion Criteria: - Male or female subject 18 years or older - Diagnosis of B-cell lymphoma (CD20+) of - follicular lymphoma (grades 1, 2, and 3) or - marginal zone lymphoma (extranodal, nodal, and splenic) - Documented relapse or progression following prior anti-neoplastic treatment. - At least 1 measurable lymph node mass that is >1.5 cm. - No active CNS lymphoma - Voluntary consent Exclusion Criteria: - Previous treatment with VELCADE - Any anti-neoplastic or experimental therapy within 3 weeks before the first dose of study drug. - Any treatment with nitrosoureas within 6 weeks before the first dose of study drug. - Treatment with Zevalin\u2122 or Bexxar\u00ae within 10 weeks before the first dose of study drug. - Rituximab, Campath\u00ae or other unconjugated therapeutic antibody within 4 weeks before the first dose of study drug. - Radiation therapy within 3 weeks before the first dose of study drug. - Major surgery within 2 weeks before the first dose of study drug. - Peripheral neuropathy or neuropathic pain - History of allergic reaction attributable to compounds containing boron or mannitol - Known anaphylaxis or hypersensitivity to any component of rituximab - Diagnosed or treated for a selected malignancies other than NHL within 5 years. - Active systemic infection requiring treatment - Female subjects must not be pregnant, breast-feeding, or become pregnant during the course of the study. - Male subjects who do not agree to use an acceptable method of contraception for the duration of the study - Any serious medical or psychiatric illness likely to interfere with participation in this clinical study - Concurrent treatment with another investigational agent. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00085696.xml"}